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Using a unique injury model of the pancreas in mouse, Xu et al. (2008) now reveal the involvement 
of neurogenin3, a marker for embryonic-type endocrine progenitor cells, in the formation of new 
insulin-producing β cells. These neurogenin3-positive facultative endocrine progenitor cells in the 
adult pancreas may be of potential value for treating diabetes.A major challenge of modern biol-
ogy is to identify the cellular origins of 
tissues, an effort that has important 
implications for the treatment of neo-
plastic and degenerative diseases. In 
the case of the pancreas, understand-
ing how insulin-producing β cells are 
generated may aid in the design of 
regenerative and cellular therapies for 
type 1 and type 2 diabetes, diseases 
characterized by loss or insufficient 
numbers of β cells (Halban, 2004). 
During embryonic development of the 
pancreas, β cells are generated from a 
transient population of endocrine pro-
genitor cells expressing the transcrip-
tion factor neurogenin3 (ngn3) (Gu et 
al., 2002; Murtaugh, 2007). However, 
during postnatal life, ngn3-positive 
progenitor cells disappear, and β cell 
expansion and maintenance relies on 
the proliferation of terminally differenti-
ated β cells. This mode of maintenance 
and repair has been demonstrated dur-
ing normal adult homeostasis as well 
as during β cell regeneration induced 
by either partial removal of the pan-
creas or specific ablation of β cells (Dor 
et al., 2004; Lee et al., 2006; Teta et al., 
2007; Brennand et al., 2007; Nir et al., 
2007). Together, these data suggested 
that the principal “natural” mode of β 
cell replacement in adult mammals 
requires pre-existing β cells.
In this issue of Cell, Xu, Heimberg, 
and colleagues now report an impor-
tant exception with their demonstration 
that β cells in adult mice can be formed 
from non-β cells (Xu et al., 2008). In 
convincing experiments, they make use of a unique model of tissue dam-
age and discover that cells expressing 
ngn3 reappear in adult mice following 
injury and give rise to new β cells. This 
study provides a clear example that 
facultative β cell progenitors exist, and 
suggests that the adult pancreas con-
tains cells that retain the potential to 
revert to an embryonic-type mode of β 
cell generation.
Xu et al. examined in detail the con-
sequences of partial duct ligation, a 
surgical procedure in which drainage 
of digestive enzymes from the exo-
crine pancreas into the duodenum is 
restricted, causing widespread degen-
eration of acinar cells and extensive 
proliferation of remaining ducts. As 
observed by Rosenberg, Duguid, and 
Vinik who developed a similar model in 
the 1980s, duct ligation results in hyper-
plasia of the islets of Langerhans, the 
structures in the pancreas in which β 
cells reside (Rosenberg, 1998). A key 
finding of Xu et al. is that in the days 
that follow partial duct ligation, ngn3 
expression is induced in the pancreas. 
To determine if these ngn3-positive cells 
can give rise to new β cells, ngn3-posi-
tive cells were isolated from the injured 
mouse pancreas by flow cytometry and 
injected into an explanted embryonic 
pancreas. Pancreatic buds from ngn3-
deficient embryos were used as recipi-
ents for the sorted ngn3-positive cells, 
because endogenous endocrine cells 
fail to develop without ngn3. Their data 
convincingly show that ngn3-positive 
cells isolated from adult mice after par-
tial duct ligation differentiate into β cells Cell 132and other pancreatic hormone-produc-
ing cells in the explanted embryonic 
pancreas. Thus, in addition to prolifera-
tion of pre-existing β cells, the appear-
ance and subsequent differentiation of 
ngn3-positive cells also contributes to 
new β cells after this type of injury.
The authors also attempted to deter-
mine the importance of ngn3 expres-
sion for islet hyperplasia (and concur-
rent β-cell production) after partial duct 
ligation in adult mice. In vivo infection of 
the adult mouse pancreas with lentivi-
ruses containing short hairpin RNA mol-
ecules directed against ngn3 reduced 
islet hyperplasia. This suggested that 
ngn3 plays an important role in the gen-
eration of new β cells in the adult fol-
lowing partial duct ligation, similar to 
its role during embryonic development. 
Proving this notion awaits an adult-
onset knockout of the ngn3 gene using 
Cre-lox technology. Finally, expres-
sion studies and lineage tracing led the 
authors to conclude that ngn3-positive 
cells emerge from the pancreatic ducts 
(Bonner-Weir et al., 2004). Definitive 
identification of the cell type that turns 
on the ngn3 gene in the adult pancreas 
and determining the precise anatomical 
niche controlling this event are impor-
tant future challenges.
What are the implications of this 
study? First, it reveals that the adult 
pancreas retains the potential to reac-
tivate its embryonic mode of β cell 
formation. It will be important to deter-
mine which source of cells offers the 
greater potential for producing new β 
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or differentiation of these newly discov-
ered adult ngn3-positive cells. In this 
regard, the pancreas looks more like 
the liver, which normally regenerates 
from injury (such as partial hepatec-
tomy) by simple proliferation of hepa-
tocytes, but following specific types of 
insults is thought to activate “faculta-
tive” stem cells known as oval cells. 
The provocative suggestion that follows 
from the current work is that patients 
with type 1 diabetes, which have lost 
the vast majority of their β cells, may 
still retain a population of cells capable 
of producing new β cells.
Naturally, this study raises multiple 
questions. For example, we do not 
know what induces the reversal of the 
pancreas to an embryonic mode of 
endocrine development. Identifying 
molecules that trigger this response 
following partial duct ligation and 
potentially other injury models, will 
provide a key missing link between tis-
sue injury and repair. In this regard, it 184 Cell 132, January 25, 2008 ©2008 Elsevwill be interesting to determine whether 
islet neogenesis-associated protein 
(INGAP) induces ngn3 expression. 
INGAP was identified in previous stud-
ies using duct ligation and is proposed 
to mediate the formation of new β cells 
(Rosenberg, 1998). The biology of adult 
ngn3-positive cells also remains mys-
terious. Do they migrate to join existing 
islets? How extensively do ngn3-pos-
itive cells or their progeny proliferate? 
Finally, the therapeutic relevance of 
these findings will have to be deter-
mined. Do ngn3-positive cells exist in 
patients with diabetes, and are there 
sufficient numbers to have a physi-
ological effect? Does the adult human 
pancreas retain the potential to reacti-
vate an embryonic-type endocrine pro-
genitor pathway in vivo or in vitro? In 
this respect, the development of new 
methods to study the dynamics of the 
postnatal pancreas in humans, such as 
non invasive imaging and lineage trac-
ing, is likely to be rewarding.ier Inc.REFEREnCEs
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